Crestmont Private Wealth’s Gilead Sciences GILD Stock Holding History

Crestmont Private Wealth’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$477K	Buy	3,775 +139	+4%	+$18.3K	0.13%	59
2026 Q1	$507K	Buy	3,636 +302	+9%	+$42.3K	0.16%	57
2025 Q4	$409K	Buy	3,334 +162	+5%	+$19.7K	0.13%	54
2025 Q3	$352K	Buy	3,172 +273	+9%	+$31K	0.12%	58
2025 Q2	$321K	Sell	2,899 -703	-20%	-$74.8K	0.12%	54
2025 Q1	$404K	Buy	3,602 +56	+2%	+$5.78K	0.17%	44
2024 Q4	$328K	Sell	3,546 -621	-15%	-$55.9K	0.15%	47
2024 Q3	$349K	Buy	4,167 +30	+0.7%	+$2.29K	0.15%	53
2024 Q2	$284K	Buy	+4,137	New	+$276K	0.14%	59

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crestmont Private Wealth's GILD Position: Q2 2026 in Review

Crestmont Private Wealth increased its Gilead Sciences (GILD) stake by 3.8% in Q2 2026, buying an estimated $18.3K and bringing the position to 3,775 shares worth $477K. The position accounts for 0.13% of the portfolio, ranked #59.

Crestmont Private Wealth first reported a position in GILD in Q2 2024 and has held it in 9 quarters since. The position peaked at $507K in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Crestmont Private Wealth held 3,775 shares of Gilead Sciences worth $477K as of Q2 2026.
Crestmont Private Wealth bought 139 Gilead Sciences shares in Q2 2026, an estimated $18.3K.
Gilead Sciences made up 0.13% of Crestmont Private Wealth's portfolio in Q2 2026, its #59 holding.
Crestmont Private Wealth first reported a position in Gilead Sciences in Q2 2024 and has held it in 9 quarters since.
Crestmont Private Wealth's Gilead Sciences position peaked at $507K in Q1 2026.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Crestmont Private Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.